NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.

Title
NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 38, Issue 4_suppl, Pages TPS261-TPS261
Publisher
American Society of Clinical Oncology (ASCO)
Online
2020-02-05
DOI
10.1200/jco.2020.38.4_suppl.tps261

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started